Board of Directors
Executive Director
Mr.
Mr. Tian currently serves as Chairman and Chief Executive Officer of JW Therapeutics. He has more than 20 years of experience in the biopharmaceutical industry, with extensive expertise in oncology commercialization, medical affairs, clinical research and development, operations management and strategic planning. Mr. Tian has long focused on innovative oncology therapies and has held multiple senior leadership positions at multinational pharmaceutical companies, leading domestic innovative pharmaceutical companies and biotechnology companies. He brings comprehensive leadership experience across product strategy, research and development, market access, commercial execution and overall corporate management.
- Prior to joining JW Therapeutics, Mr. Tian served as General Manager of the Oncology Business at Changchun GeneScience Pharmaceuticals, where he was responsible for building the oncology business platform from the ground up. In this role, he led team building, product introduction, R&D strategy optimization, market access and commercial system development, and drove rapid growth of the relevant business. Previously, Mr. Tian served as Chief Executive Officer and Director of Shanghai Kinnjiu Biotechnology, where he was responsible for the company’s overall operations, strategic development, and the clinical development and commercialization planning of innovative oncology assets.
- From 2019 to 2021, Mr. Tian served as Deputy General Manager of the Oncology Business Unit at Hengrui Pharmaceuticals, where he was responsible for marketing and medical affairs. He led the launch and commercialization of the PD-1 product and advanced the launch preparation and commercialization of multiple innovative oncology medicines. Earlier in his career, Mr. Tian served as Marketing Director at Roche Pharmaceuticals, where he was responsible for several key oncology products. He also served as Senior International Product Manager at Pfizer, supporting business expansion across multiple emerging markets.
- Mr. Tian graduated from Shanghai Jiao Tong University School of Medicine with a master’s degree in hematology.
Non-Executive Director
Dr.
Dr. Yiping James Li, M.D. (“Dr. Li”) is a co-founder of the Company and served as Chief Executive Officer from February 2016 to July 2024, and as Chairman of the Board from July 2020 to March 2025.
- Dr. Li currently serves as a Venture Partner at Frazier Life Sciences, a U.S.-based venture capital firm headquartered in California. He is also a co-founder and Chairman of the Board of AirNexis Therapeutics, a clinical-stage biotechnology company based in Palo Alto, California, focused on the development of innovative therapies for respiratory diseases. Prior to founding JW Therapeutics, Dr. Li held various leadership roles in the biopharmaceutical industry, including Founding General Manager of Amgen Greater China, Venture Partner at Kleiner Perkins, and senior positions at Merck & Co., Inc.
- Dr. Li received his medical degree from Shanghai Medical College of Fudan University (formerly known as Shanghai Medical University) in the PRC in July 1987, and a Master of Science degree in Microbiology from the University of Montana in the United States in December 1991.
Ms.
Ms. Xing Gao (“Ms. Gao”) is a non-executive Director of our Company. She joined our Company on May 22, 2020 and was appointed as non-executive Director on the same date. She is primarily responsible for supervising and providing oversight to the Board.
- Ms. Gao has over 15 years of healthcare investment related experience. She currently serves as a principal at Beijing Panmao Consulting Co., Ltd.* (北京磐茂諮詢有限公司), a member of a leading alternative asset manager in the PRC. Prior to that, she worked as associate at N M Rothschild & Sons Limited from October 2011 to June 2013 and as an analyst at the Bank of America Merrill Lynch from June 2007 to September 2011.
- Ms. Gao obtained a bachelor’s degree in biochemical engineering from University College London in the United Kingdom in August 2008 and a master of business administration degree from Harvard Business School in the United States in May 2015.
Independent Non-Executive Director
Mr.
Mr. Kin Cheong Kelvin Ho (“Mr. Ho”) is an independent non-executive Director of our Company. He joined our Group on October 22, 2020 and was appointed as an independent non-executive Director on the same date. He is primarily responsible for providing independent view to the Board. Mr. Ho has over 29 years of experience in finance and accounting, company secretary, initial public offering, takeover, deposition and debt restructuring.
- Mr. Ho was appointed as an independent non-executive director of CECEP COSTIN New Materials Group Limited (in provisional liquidation) (“CECEP COSTIN”) (HKSE: 2228), a company listed on the Main Board of the Stock Exchange, since August 6, 2018. Based on published information, CECEP COSTIN received a winding up petition and a summons for the appointment of joint provisional liquidators dated October 30, 2017. Mr. Ho’s appointment was subsequent to the winding up petition against CECEP COSTIN and he was appointed by the joint provisional liquidators to meet the relevant requirements under the Listing Rules. He has resigned as an independent non-executive director on February 8, 2022. Mr. Ho has been appointed as an independent non-executive director of Rosan Resources Holdings Limited (HKSE: 0578) since July 1, 2020 and has resigned on November 1, 2022. He was also a non-executive director of E-rental Car Company Limited (now known as China Wood International Holding Co., Limited) (HKSE: 1822) from April 11, 2016 for a one-year term and he was an independent non-executive director of Cheung Tai Hong Holdings Limited (now known as ITC Properties Group Limited) (HKSE: 0199) from October 29, 2001 to May 20, 2003. Mr. Ho is currently also respectively appointed as an independent non-executive director of Yadong Group Holdings Limited (HKSE: 1795) since October 21, 2020 and an independent non-executive director of MicroTech Medical (Hangzhou) Co., Ltd. (HKSE: 2235) since April 21, 2021. In addition, he is also the independent non-executive director of Green Leader Holdings Group Limited (HKSE: 00061) since August 5, 2020. The securities of the above companies are listed on the Main Board of the Stock Exchange.
- Mr. Ho holds a Bachelor Degree in Business Administration (Hons.), major in Accounting, from Hong Kong Baptist University (previously known as Hong Kong Baptist College) in Hong Kong in November 1990. He is an associate member of the Hong Kong Institute of Certified Public Accountants, and a fellow member of the Association of Chartered Certified Accountants.
Dr.
Dr. Debra Yu (“Dr. Yu”) is an independent non-executive Director of our Company. She joined our Group on March 1, 2023 and was appointed as an independent non-executive Director on the same date. She is primarily responsible for providing independent view to the Board. Dr. Yu has more than 36 years of experience in strategy, business development, alliance management, investment banking, capital markets and venture capital. She is currently a director of Ascentage Pharma (a company dually listed on Nasdaq under the symbol AAPG and on HKG under the symbol 6855 since November 2024) and MeiraGTx (a company listed on Nasdaq under the symbol MGTX) since April 2022.
- She served as the president of LianBio (a company listed on Nasdaq under the symbol LIAN) from October 2019 to December 2022, where she also served as the chief business officer from October 2019 to September 2021 and the chief strategy officer from October 2021 to December 2022. Prior to that, Dr. Yu held leadership positions at various reputable companies, including managing director and head of cross border investment banking of China Renaissance (US) Securities from August 2016 to September 2019, managing director of Labrador Advisors, LLC from July 2009 to June 2016, vice president and head of strategy of WuXi AppTec, Inc. from 2008 to 2009 and senior director and team leader of the Pfizer Investments Group and Worldwide Business Development at Pfizer, Inc. from 2004 to 2008. Earlier in her career, Dr. Yu served as the managing director and a general partner of two venture capital firms in the San Francisco Bay Area which focus their investments in the life sciences sector.
- Dr. Yu received a bachelor’s degree in molecular biology from Princeton University in June 1986 and subsequently received a medical degree from Harvard Medical School in March 1992.
Mr.
Mr. Peng Kuan Chan (“Mr. Chan”) is an independent non-executive Director of our Company. He joined the Group on August 28, 2024 and was appointed as an independent non-executive Director on the same date. He is primarily responsible for supervising and providing oversight to the Board. Mr. Chan has more than 31 years of experience in finance and banking.
- Prior to joining the Group, Mr. Chan has been serving as an independent non-executive director of CANbridge Pharmaceuticals Inc., a company listed on the Stock Exchange (HKSE: 1228) and Yonghe Medical Group Co., Ltd., a company listed on the Stock Exchange (HKSE: 2279) since June 2021, respectively. Mr. Chan has been appointed as an independent non-executive director at Visen Pharmaceuticals (HKSE: 2561) effective as of April 1, 2021, which commenced its trading on the Stock Exchange on March 21, 2025. Mr. Chan served as an independent non-executive director at Yincheng International Holding Co., Ltd., a company listed on the Stock Exchange (HKSE: 1902) from February 2019 to November 2024 and resigned effective from November 16, 2024. From October 2017 to May 2019, Mr. Chan served as chief financial officer of Elegance Optical International Holdings Limited, a company listed on the Stock Exchange (HKSE: 907) and served as chief operating officer of CITIC Merchant Co., Limited (中信國通投資管理有限公司) from January 2012 to September 2017. Prior to that, Mr. Chan was the head of Asia CIG and Cleantech of Piper Jaffray Asia Limited from February 2011 to November 2011. From March 2005 to January 2011, Mr. Chan also worked at BNP Paribas Capital (Asia Pacific) Limited with his last position as a managing director of Corporate Finance — Greater China Coverage department. From August 2000 to December 2004, Mr. Chan served as an executive director of Sanyuan Group Limited (三元集團有限公司) (“Sanyuan Group”), a company incorporated in Hong Kong and principally engaged in property investment and biopharmaceuticals, which was delisted from the Stock Exchange in December 2009. Mr. Chan’s mission with the Sanyuan Group was to restructure its business activities and materialize its debt restructuring plan.
- Mr. Chan obtained his bachelor’s degree in commerce from the University of Canterbury in New Zealand in May 1989. He received his master’s degree in applied finance from Macquarie University in Australia in November 1998. Mr. Chan has been a member of the Hong Kong Institute of Certified Public Accountants (previously known as Hong Kong Society of Accountants) since July 1993. He obtained his professional qualification as a Chartered Accountant in November 1992 from the Chartered Accountants Australia and New Zealand (previously known as the Institute of Chartered Accountants of New Zealand).